What additional medication can be added to a patient with poorly controlled diabetes, currently taking Janumet (sitagliptin and metformin) and Invokana (canagliflozin), with an elevated Hemoglobin A1C (HbA1C) level?

Adding Medication for A1C 11% on Janumet and Invokana

Immediate Recommendation

Add basal insulin immediately, starting at 10 units once daily (or 0.1-0.2 units/kg/day), and strongly consider adding a GLP-1 receptor agonist such as liraglutide or dulaglutide for this severely elevated A1C of 11%. 1, 2

---

Why Insulin is Essential at This A1C Level

• At A1C 11%, only insulin or combination injectable therapy can achieve adequate glycemic control, as most oral agents reduce A1C by less than 1%, making them insufficient at this baseline 1, 3
• Insulin is the most effective glucose-lowering agent when A1C is ≥9.0%, and this patient's A1C of 11% warrants aggressive treatment to prevent metabolic decompensation 1, 4
• Prolonged severe hyperglycemia (A1C >9% for months) should be specifically avoided due to increased risk of complications and irreversible beta-cell damage 1, 3

---

Optimal Treatment Strategy: Basal Insulin + GLP-1 RA

Basal Insulin Initiation

• Start with 10 units of basal insulin (glargine, detemir, or degludec) once daily, administered at the same time each day 1, 5
• Titrate by 2-4 units every 3 days until fasting glucose reaches 80-130 mg/dL 1, 2
  • Increase by 4 units if fasting glucose ≥180 mg/dL 2, 5
  • Increase by 2 units if fasting glucose 140-179 mg/dL 2, 5

Adding GLP-1 Receptor Agonist

• GLP-1 RAs (liraglutide, semaglutide, dulaglutide) provide A1C reductions of 1.5-2.5% with weight loss benefits, making them ideal for combination with basal insulin 1, 6, 4
• When adding a GLP-1 RA to existing therapy, reduce basal insulin dose by 20% if A1C ≤8% to prevent hypoglycemia 7
• The combination of metformin, SGLT2 inhibitor (Invokana), basal insulin, and GLP-1 RA addresses multiple pathophysiologic defects while minimizing hypoglycemia risk 2, 7

Evidence Supporting This Combination

• Studies show GLP-1 RAs added to basal insulin reduce A1C and body weight, with similar or greater A1C reduction compared to adding mealtime insulin, but with weight loss instead of weight gain and less hypoglycemia 7, 4
• At baseline A1C >9%, GLP-1 RAs (exenatide QW, liraglutide, dulaglutide) showed 0.2-0.3% greater A1C reductions than insulin glargine, with superior weight outcomes 4
• In patients with A1C >11%, the combination of metformin with GLP-1 RA therapy reduced A1C from 11.6% to approximately 6-7% 4

---

Continue Current Medications

• Maintain metformin (in Janumet) as the foundation of therapy unless contraindicated, as it provides cardiovascular benefits and reduces insulin requirements 1, 2, 3
• Continue Invokana (canagliflozin), as SGLT2 inhibitors with proven cardiovascular benefit are recommended independent of A1C for patients with diabetes 1
• Discontinue sitagliptin (in Janumet) when adding GLP-1 RA, as both are incretin-based therapies and should not be used together 1

---

Alternative if GLP-1 RA Not Feasible

Basal-Bolus Insulin Regimen

• If GLP-1 RA is not affordable or tolerated, initiate basal-bolus insulin immediately for A1C 11% 1, 2
• Calculate total daily insulin dose as 0.3-0.5 units/kg/day, giving 50% as basal insulin and 50% as prandial insulin divided among meals 2, 5
• Start prandial insulin with 4 units of rapid-acting insulin before the largest meal, or 10% of basal dose 1, 2
• Titrate prandial insulin by 1-2 units or 10-15% twice weekly based on 2-hour postprandial glucose readings 1, 2

---

Critical Monitoring Timeline

• Check fasting blood glucose daily during insulin titration to guide dose adjustments 2, 5
• Reassess A1C after 3 months to determine if additional intensification is needed 1, 3
• If A1C remains >7% after 3-6 months despite optimized therapy, further treatment intensification is required 1, 3

---

Important Caveats and Pitfalls to Avoid

Do Not Delay Injectable Therapy

• Delaying insulin or GLP-1 RA initiation while trying additional oral agents prolongs exposure to severe hyperglycemia and increases complication risk 1, 3
• Adding a third oral agent without injectable therapy at A1C 11% will have insufficient glucose-lowering effect, as most oral agents reduce A1C by <1% 1, 3

Hypoglycemia Risk Management

• If hypoglycemia occurs, determine the cause and reduce insulin dose by 10-20% immediately 2, 5
• Educate patient on recognition and treatment of hypoglycemia with 15 grams of fast-acting carbohydrate 5
• Provide written instructions for insulin dose adjustments based on glucose patterns 2

Weight Considerations

• Insulin intensification causes weight gain, while GLP-1 RAs cause weight loss, making combination therapy advantageous for overweight patients 7, 4
• SGLT2 inhibitors (Invokana) provide modest weight loss, which complements the regimen 1

---

Practical Implementation Steps

1. Start basal insulin 10 units at bedtime (or 0.1-0.2 units/kg/day) 1, 5
2. Add GLP-1 RA (liraglutide 0.6 mg daily, titrate to 1.2-1.8 mg; or dulaglutide 0.75-1.5 mg weekly) 6, 4
3. Discontinue sitagliptin component of Janumet, continue metformin 1
4. Continue Invokana (canagliflozin) for cardiovascular and renal benefits 1
5. Titrate basal insulin every 3 days based on fasting glucose 2, 5
6. Monitor for gastrointestinal side effects from GLP-1 RA, especially during initiation 6, 7
7. Reassess A1C in 3 months and intensify further if needed 1, 3